Conduit Pharmaceuticals (CDT) News Today $0.62 +0.03 (+5.08%) Closing price 04/9/2025 04:00 PM EasternExtended Trading$0.60 -0.02 (-3.39%) As of 04/9/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Conduit expands parntership with SarborgApril 8 at 10:57 AM | markets.businessinsider.comConduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline OptimizationApril 7 at 11:26 AM | markets.businessinsider.comAnalyzing Conduit Pharmaceuticals (CDT) and Its PeersApril 6, 2025 | americanbankingnews.comConduit Pharmaceuticals receives U.S. patent approval for AZD1656April 2, 2025 | markets.businessinsider.comConduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune DiseasesMarch 31, 2025 | globenewswire.comConduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline DevelopmentMarch 21, 2025 | nasdaq.comConduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656March 21, 2025 | nasdaq.comConduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904March 20, 2025 | markets.businessinsider.comConduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904March 19, 2025 | globenewswire.comConduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price RegainingMarch 8, 2025 | nasdaq.comIs Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comConduit granted extension by Nasdaq to regain complianceMarch 6, 2025 | markets.businessinsider.comConduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing PanelMarch 6, 2025 | globenewswire.comConduit Pharmaceuticals progresses Phase II of AI initiative with SarborgFebruary 20, 2025 | markets.businessinsider.comConduit Progresses Phase II of its AI Initiative with SarborgFebruary 20, 2025 | globenewswire.comConduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus ModelFebruary 13, 2025 | globenewswire.comConduit announces debt repayment, conversion of senior secured noteFebruary 11, 2025 | markets.businessinsider.comConduit Pharmaceuticals settles debt, converts senior noteFebruary 11, 2025 | msn.comConduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured NoteFebruary 11, 2025 | globenewswire.comConduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase IIFebruary 8, 2025 | insidermonkey.comConduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug DevelopmentFebruary 7, 2025 | markets.businessinsider.comConduit Pharmaceuticals transitions to Phase II of Sarborg collanFebruary 7, 2025 | markets.businessinsider.comConduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug DevelopmentFebruary 7, 2025 | globenewswire.comConduit Pharmaceuticals files to sell 5.9M shares of common stock for holdersFebruary 6, 2025 | markets.businessinsider.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Significant Decrease in Short InterestConduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,750,000 shares, a drop of 67.6% from the December 31st total of 11,570,000 shares. Based on an average daily volume of 52,100,000 shares, the short-interest ratio is currently 0.1 days.January 28, 2025 | marketbeat.comConduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial IntelligenceJanuary 28, 2025 | globenewswire.comConduit Pharmaceuticals board approves 1-for-100 reverse stock splitJanuary 24, 2025 | markets.businessinsider.comMurphy Canyon stock hits 52-week low at $0.05 amid steep declineJanuary 23, 2025 | msn.comConduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standardsJanuary 23, 2025 | msn.comConduit Pharmaceuticals Approves 1-for-100 Reverse Stock Split, Stock FallsJanuary 23, 2025 | markets.businessinsider.comConduit Pharmaceuticals Inc. Announces Reverse Stock SplitJanuary 23, 2025 | globenewswire.comConduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune PipelineJanuary 23, 2025 | markets.businessinsider.comConduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse splitDecember 23, 2024 | investing.comConduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock SplitDecember 21, 2024 | markets.businessinsider.comConduit and Sarborg link to optimise AI drug developmentDecember 14, 2024 | msn.comConduit Pharmaceuticals to enter agreement with SARBORDecember 13, 2024 | markets.businessinsider.comConduit Collaborates With Sarborg To Facilitate Drug Development, Stock Up In Pre-MarketDecember 12, 2024 | markets.businessinsider.comConduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and CyberneticsDecember 12, 2024 | globenewswire.comConduit Pharmaceuticals receives further patent approval for AZD1656November 21, 2024 | markets.businessinsider.comWhat's Going On With Conduit Pharmaceuticals Shares Today?November 21, 2024 | benzinga.comConduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune DisordersNovember 21, 2024 | globenewswire.comConduit Pharmaceuticals Announces Leadership Changes and Bylaws UpdateNovember 20, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces Appointment of Simon Fry to Board of DirectorsNovember 19, 2024 | globenewswire.comConduit Pharmaceuticals announces new addition to autoimmune pipelineNovember 5, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces New Addition to its Autoimmune PipelineNovember 4, 2024 | globenewswire.comConduit Pharmaceuticals Secures Funding and Modifies Debt AgreementsNovember 1, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces Debt Restructuring and Additional NotesNovember 1, 2024 | globenewswire.comLtd Nirland Sells 939,009 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) StockOctober 8, 2024 | insidertrades.comConduit Pharmaceuticals executives sell shares worth over $297kOctober 4, 2024 | investing.comConduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells $33,317.70 in StockOctober 3, 2024 | insidertrades.com Remove Ads Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address CDT Media Mentions By Week CDT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDT News Sentiment▼0.450.82▲Average Medical News Sentiment CDT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDT Articles This Week▼41▲CDT Articles Average Week Remove Ads Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aprea Therapeutics News Athira Pharma News TherapeuticsMD News COSCIENS Biopharma News PHAXIAM Therapeutics News Moleculin Biotech News Biomerica News Trinity Biotech News GeoVax Labs News Sensei Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDT) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersThe Most Bullish Metric For Stocks (NOT Volume…)Before placing a single trade, Tim Sykes always checks one key bullish metric. It’s the same signal that has s...MillPub | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts